ArticleCureus2025
A Case of Piperacillin-Induced Immune Thrombocytopenia: Diagnostic Challenges and Management.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: rapid exacerbation of autoimmune hemolysis and severe immune - mediated thrombocytopenia induced by piperacillin - tazobactam.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced immune thrombocytopenia (DITP) is a rare yet critical disorder that requires prompt recognition and discontinuation of the causative drug to prevent severe complications. In DITP, platelet-reactive antibodies lead to significant platelet destruction. Heparin-induced thrombocytopenia is the most well-studied; yet, antibiotics have also been described. Herein is a case of a 97-year-old woman with a history of hypertension and hyperlipidemia who was admitted with rhabdomyolysis and sepsis secondary to choledocholithiasis and gallstone pancreatitis. She was started on intravenous fluids and broad-spectrum antibiotics, including piperacillin-tazobactam and vancomycin. Within days, her platelet count dropped from 323,000/μL to 1,000/μL. Schistocytes and hemolysis were absent on a peripheral smear. The patient had normal coagulation studies, and she had a low 4T (thrombocytopenia, timing of platelet count fall, thrombosis or other sequelae, and other causes for thrombocytopenia) score, ruling out thrombotic microangiopathies, such as disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), and heparin-induced thrombocytopenia (HIT), respectively. While immune thrombocytopenic purpura (ITP) was seriously considered, the temporal relationship between the drop in platelet count and the administration of broad-spectrum antibiotics led to greater suspicion of DITP. Piperacillin was suspected to be the cause and was promptly discontinued. The suspicion was subsequently confirmed, as supported by the detection of positive drug-dependent IgG antibodies. The patient's platelet count normalized within a week after stopping piperacillin and receiving IV immunoglobulin (1 g/kg). Hence, DITP needs to be considered among other causes in patients with acute severe thrombocytopenia, as early recognition and prompt cessation of the offending agent are important for preventing life-threatening hemorrhagic sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.